Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.60
-0.0250-0.69%
Volume:615.97K
Turnover:2.14M
Market Cap:112.49M
PE:-0.87
High:3.61
Open:3.58
Low:3.35
Close:3.62
52wk High:49.25
52wk Low:3.35
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.84
T/O Rate:3.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.51
PE(LYR):-1.26

Loading ...

Vector Science and Therapeutics Grants Stock Options to Officer

TIPRANKS
·
Sep 26

Silexion Therapeutics Shareholders Reject Capital Structure Changes

TIPRANKS
·
Sep 26

Stoke Therapeutics appoints new independent board director

TIPRANKS
·
Sep 26

Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice

TIPRANKS
·
Sep 26

Tempest Therapeutics files to sell 9.53M shares of common stock for holders

TIPRANKS
·
Sep 26

NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY

Benzinga Earnings
·
Sep 26

Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says

MT Newswires Live
·
Sep 26

Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and Nanobiotix (NBTX)

TIPRANKS
·
Sep 25

Damora Therapeutics price target raised, named a Best Idea at Guggenheim

TIPRANKS
·
Sep 25

Thalia Therapeutics Completes Initial Synthesis for Cardiovascular siRNA Program

MT Newswires Live
·
Sep 25

Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline

TIPRANKS
·
Sep 25

City Therapeutics Files for IPO

Dow Jones
·
Sep 25

Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

GlobeNewswire
·
Sep 25

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

GlobeNewswire
·
Sep 25

Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade

MT Newswires Live
·
Sep 25

Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says

MT Newswires Live
·
Sep 25

Tempest Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 25

Arcturus Therapeutics Raised to Buy from Neutral by Citigroup

Dow Jones
·
Sep 24

Tempest Therapeutics price target lowered to $7 from $11 at H.C. Wainwright

TIPRANKS
·
Sep 24

Oruka Therapeutics Price Target Maintained with a $165.00/Share by Wedbush

Dow Jones
·
Sep 24